Literature DB >> 16897607

Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study.

Y F Tai1, R L Ahsan, J G de Yébenes, N Pavese, D J Brooks, P Piccini.   

Abstract

We analyzed (18)F-dopa PET data from 11 members of kindreds with familial progressive supranuclear palsy (PSP) to characterize their cerebral dopaminergic dysfunction. Three clinically-affected PSP patients showed reduced (18)F-dopa uptake in the striatum, orbitofrontal cortex and amygdala. One asymptomatic subject exhibited progressive putamen dopaminergic dysfunction. 60% of subjects with abnormal (18)F-dopa scans developed PSP subsequently. This is the first in vivo documentation of cortical dopaminergic deficiency in PSP. Reduced striatal (18)F-dopa uptake in susceptible relatives may predict later clinical disease.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16897607     DOI： 10.1007/s00702-006-0536-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  12 in total

1.  PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

Authors:  J C STEELE; J C RICHARDSON; J OLSZEWSKI
Journal:  Arch Neurol       Date:  1964-04

2.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations.

Authors:  C S Patlak; R G Blasberg
Journal:  J Cereb Blood Flow Metab       Date:  1985-12       Impact factor: 6.200

3.  Clinical genetics of familial progressive supranuclear palsy.

Authors:  A Rojo; R S Pernaute; A Fontán; P G Ruíz; J Honnorat; T Lynch; S Chin; I Gonzalo; A Rábano; A Martínez; S Daniel; P Pramstaller; H Morris; N Wood; A Lees; C Tabernero; T Nyggard; A C Jackson; A Hanson; J G de Yébenes; P Pramsteller
Journal:  Brain       Date:  1999-07       Impact factor: 13.501

Review 4.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Authors:  I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

5.  Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography.

Authors:  P Piccini; J de Yebenez; A J Lees; R Ceravolo; N Turjanski; P Pramstaller; D J Brooks
Journal:  Arch Neurol       Date:  2001-11

6.  Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study.

Authors:  Walter Pirker; Schiva Djamshidian; Susanne Asenbaum; Willibald Gerschlager; Gotthard Tribl; Martha Hoffmann; Thomas Brücke
Journal:  Mov Disord       Date:  2002-01       Impact factor: 10.338

Review 7.  PET studies in progressive supranuclear palsy.

Authors:  D J Brooks
Journal:  J Neural Transm Suppl       Date:  1994

8.  Neurodegeneration in the limbic and paralimbic system in progressive supranuclear palsy.

Authors:  Y Higuchi; T Iwaki; J Tateishi
Journal:  Neuropathol Appl Neurobiol       Date:  1995-06       Impact factor: 8.090

9.  Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.

Authors:  G Chinaglia; F J Alvarez; A Probst; J M Palacios
Journal:  Neuroscience       Date:  1992-07       Impact factor: 3.590

10.  Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.

Authors:  Naheed L Khan; David J Brooks; Nicola Pavese; Mary G Sweeney; Nicholas W Wood; Andrew J Lees; Paola Piccini
Journal:  Brain       Date:  2002-10       Impact factor: 13.501
View more
  1 in total

Review 1.  Accumulation of Tau Protein, Metabolism and Perfusion-Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS).

Authors:  Piotr Alster; Natalia Katarzyna Madetko; Dariusz Mariusz Koziorowski; Leszek Królicki; Sławomir Budrewicz; Andrzej Friedman
Journal:  Front Neurol       Date:  2019-02-14       Impact factor: 4.003
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.